Paul von Autenried net worth and biography

Paul von Autenried Biography and Net Worth

Paul von Autenried is Chief Information Officer & Senior Vice President at Bristol Myers Squibb Co. and Chief Information Officer & Senior Vice President for Medarex, Inc. (a subsidiary of Bristol Myers Squibb Co.). He is also on the board of Penn Medicine Princeton Health and QuickBase, Inc. and Member of The CIO Strategy Exchange, Trustee & Member-Research Board at Princeton Healthcare System Holding, Inc. and Member of The Research Board, Inc.

In the past he occupied the position of Systems Engineer at HP, Inc. and Director-Sales Systems at Kraft General Foods Corp.

Mr. Von Autenried received an undergraduate degree and a graduate degree from Stevens Institute of Technology.

What is Paul von Autenried's net worth?: The estimated net worth of Paul von Autenried is at least $6.20 million as of November 25th, 2020. Mr. von Autenried owns 126,698 shares of Bristol-Myers Squibb stock worth more than $6,199,333 as of April 20th. This net worth approximation does not reflect any other investments that Mr. von Autenried may own. Learn More about Paul von Autenried's net worth.
How do I contact Paul von Autenried?: The corporate mailing address for Mr. von Autenried and other Bristol-Myers Squibb executives is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. Bristol-Myers Squibb can also be reached via phone at (212) 546-4000 and via email at [email protected]. Learn More on Paul von Autenried's contact information.
Has Paul von Autenried been buying or selling shares of Bristol-Myers Squibb?: Paul von Autenried has not been actively trading shares of Bristol-Myers Squibb within the last three months. Most recently, Autenried Paul Von sold 17,353 shares of the business's stock in a transaction on Wednesday, November 24th. The shares were sold at an average price of $56.92, for a transaction totalling $987,732.76. Learn More on Paul von Autenried's trading history.
Who are Bristol-Myers Squibb's active insiders?: Bristol-Myers Squibb's insider roster includes Mark Alles (CEO), Christopher Boerner (EVP), Giovanni Caforio (CEO), Adam Dubow (SVP), Joseph Eid (SVP), John Elicker (EVP), David Elkins (CFO), Sandra Leung (EVP), Dinesh Paliwal (Director), Robert Plenge (EVP), Ann Powell (EVP), Theodore Samuels, II (Director), Karen Santiago (SVP), Louis Schmukler (EVP), Rupert Vessey (EVP), and Paul von Autenried (EVP). Learn More on Bristol-Myers Squibb's active insiders.
Are insiders buying or selling shares of Bristol-Myers Squibb?: During the last year, Bristol-Myers Squibb insiders bought shares 3 times. They purchased a total of 13,571 shares worth more than $672,994.06. During the last year, insiders at the biopharmaceutical company sold shares 3 times. They sold a total of 69,103 shares worth more than $4,525,215.08. The most recent insider tranaction occured on December, 5th when CEO Christopher S Boerner bought 2,000 shares worth more than $99,560.00. Insiders at Bristol-Myers Squibb own 0.1% of the company. Learn More about insider trades at Bristol-Myers Squibb.
Information on this page was last updated on 12/5/2023.

Paul von Autenried Insider Trading History at Bristol-Myers Squibb

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/24/2021	Sell	17,353	$56.92	$987,732.76
11/22/2021	Sell	18,363	$57.17	$1,049,812.71
11/25/2020	Sell	3	$63.50	$190.50	126,698
5/2/2016	Sell	37,258	$71.93	$2,679,967.94	128,463
8/19/2014	Sell	20,000	$49.89	$997,800.00
6/10/2013	Sell	25,000	$47.24	$1,181,000.00

Paul von Autenried Buying and Selling Activity at Bristol-Myers Squibb

Bristol-Myers Squibb Company Overview

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Today's Range

Now: $48.93

$48.12

$49.05

50 Day Range

MA: $51.23

$47.83

$54.40

2 Week Range

Now: $48.93

$47.58

$70.93

Volume

10,272,342 shs

Average Volume

15,709,757 shs

Market Capitalization

$99.17 billion

P/E Ratio

12.68

Dividend Yield

5.02%

Beta

0.39

Urgent alert: open this for a huge profit potential

From Timothy Sykes | Ad

This groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo, or CNBC.

See Tim’s instructions to make this remarkably simple trade right here